Bayer’s MRI contrast agent gets FDA approval

Bayer’s MRI contrast agent gets FDA approval

Bayer AG said U.S. regulators approved its contrast agent for use in magnetic resonance imaging (MRI) to assess patients with known or suspected coronary artery disease. The injection, Gadavist, is an approved agent for use in MRI of the central nervous system and breasts. Gadavist is the only contrast agent approved by the FDA for use in cardiacMR, Bayer said.

Reuters

Related Stories

No stories found.
Aster Medical Journal
www.theamj.org